Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline*

BRENDA M. BUTTON,1 CHRISTINE WILSON,2 RUTH DENTICE,3 NARELLE S. COX,4 ANNA MIDDLETON,5 ESTA TANNENBAUM,6 JENNIFER BISHOP,7 ROBYN COBB,8 KATE BURTON,8 MICHELLE WOOD,8 FIONA MORAN,8 RYAN BLACK,2 SUMMAR BOWEN,9 ROSEMARY DAY,10 JULIE DEPIAZZI,9 KATHERINE DOIRON,11 MICHAEL DOUMIT,12 TIFFANY DWYER,3,13 ALISON ELLIOT,5 LOUISE FULLER,1 KATHLEEN HALL,8 MATTHEW HUTCHINS,14 MELINDA KERR,6 ANNEMARIE L. LEE,1 CHRISTINA MANS,15 LAUREN O’CONNOR,16 RANJANA STEWARD,1 ANGELA POTTER,17 TSHEPO RASEKABA,1 REBECCA SCOONES,18 BEN TARRANT,1 NATHAN WARD,19 SAMANTHA WEST,7 DIANNE WHITE,19 LISA WILSON,1 JAMIE WOOD20 AND ANNE E. HOLLAND4

1The Alfred Hospital,4La Trobe University,6The Royal Children’s Hospital, Melbourne, Victoria, 8The Prince Charles Hospital, 2Lady Cilento Children’s Hospital, 14Mater Health Services, Brisbane, 11Bond University/Pindara Private Hospital, 16Gold Coast University Hospital, Gold Coast, Queensland, 9Royal Prince Alfred Hospital, 5The Children’s Hospital at Westmead, 7Westmead Hospital, 15Sydney Children’s Hospital, University of Sydney, Sydney, 10John Hunter Children’s Hospital, Newcastle, New South Wales, 9Princess Margaret Hospital, 20Sir Charles Gairdner Hospital and Institute for Respiratory Health, Perth, Western Australia, 17Women’s & Children’s Hospital, 19Royal Adelaide Hospital, Adelaide, South Australia, Australia, 18Waikato DHB, Hamilton and 18Starship Children’s Health, Auckland, New Zealand

ABSTRACT

Physiotherapy management is a key element of care for people with cystic fibrosis (CF) throughout the lifespan. Although considerable evidence exists to support physiotherapy management of CF, there is documented variation in practice. The aim of this guideline is to optimize the physiotherapy management of people with CF in Australia and New Zealand. A systematic review of the literature in key areas of physiotherapy practice for CF was undertaken. Recommendations were formulated based on National Health and Medical Research Council (Australia) guidelines and considered the quality, quantity and level of the evidence; the consistency of the body of evidence; the likely clinical impact; and applicability to physiotherapy practice in Australia and New Zealand. A total of 30 recommendations were made for airway clearance therapy, inhalation therapy, exercise and musculoskeletal management. These recommendations can be used to underpin the provision of evidence-based physiotherapy care to people with CF in Australia and New Zealand.

Key words: airway clearance, cystic fibrosis, exercise, inhalation therapy, physiotherapy.

Abbreviations: ACBT, active cycle of breathing technique; ACT, airway clearance techniques; AD, Autogenic drainage; CF, cystic fibrosis; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s; GOR, gastro-oesophageal reflux; PEP, Positive expiratory pressure.

BACKGROUND

The aim of this Clinical Practice Guideline is to optimize physiotherapy management of people with cystic fibrosis (CF) in Australia and New Zealand. Recommendations for key areas of physiotherapy management are provided, including airway clearance therapy, inhalation therapy, exercise and musculoskeletal management. This Clinical Practice Guideline builds on a previous Consensus Statement for physiotherapy management of CF in Australia1 and is informed by an evaluation of its uptake and impact.2

*The extended version of the clinical practice guidelines presented in this paper can be found in the online supplementary information. Any reference to the online supplementary information should cite this Respirology paper as the primary publication.

Correspondence: Brenda M. Button, Physiotherapy Department, The Alfred Hospital, Commercial Rd, Prahran, Melbourne, Vic. 3004, Australia. Email: b.button@alfred.org.au

Received 23 October 2015; invited to revise 14 December 2015; revised 13 January 2016; accepted 8 February 2016 (Associate Editor: Stacey Peterson-Carmichael).

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2016 The Authors
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology

doi: 10.1111/resp.12764
METHODS

All physiotherapists who were regularly caring for people with CF across paediatric and adult settings in Australia and New Zealand were invited to participate in guideline development. A systematic literature search was undertaken for each topic area up until June 2014, using MEDLINE, CINAHL, EMBASE and PEDro. Data from each included study were extracted into an evidence table by one reviewer and checked by a second reviewer. Quality was graded according to the NHMRC evidence hierarchy. Recommendations were formulated based on the quality, quantity and level of the evidence; the consistency of the body of evidence; the likely clinical impact; and generalizability and applicability to physiotherapy practice in Australia and New Zealand. Areas of importance to physiotherapy practice, but with insufficient evidence to make recommendations, were highlighted. Updates of each section were prepared by a writing group and circulated to all authors for comment and revision. The draft document was offered to stakeholders for comment, including CF physicians, CF consumers, allied health professionals and physiotherapists who were not part of the writing group.

This guideline provides recommendations for clinical physiotherapy practice and a summary of the evidence that underpins them. More details regarding the evidence underpinning the recommendations and application of the physiotherapy techniques can be found in the Supplementary Appendix S1.

AIRWAY CLEARANCE TECHNIQUES

The aim of airway clearance techniques (ACT) is to clear sputum from the airway, in order to optimize respiratory status and slow disease progression. ACT are frequently described as a ‘cornerstone’ of CF treatment. A Cochrane review concluded that ACT have short-term beneficial effects on mucus transport in CF. One uncontrolled study evaluated the effects of withdrawing airway clearance for 3 weeks and found a detrimental effect on pulmonary function. Because of ethical concerns regarding withholding such a well-established treatment, it is considered unlikely that more robust controlled trials of the long-term impact of ACT in CF will be conducted.

A number of effective ACT are available. The active cycle of breathing technique (ACBT) consists of breathing control, thoracic expansion exercises and forced expirations. The ACBT is effective for clearance of respiratory secretions with results comparable to other widely used ACT. The ACBT can be performed by all patients who can follow instructions and is useful in all stages of disease. Positive expiratory pressure (PEP) therapy is defined as breathing against a PEP of 10–20 cmH2O using a mask or mouthpiece. A Cochrane review concluded that PEP was equally effective as other forms of ACT and that patients may prefer PEP. Oscillating PEP combines oscillation of airflow with PEP, in order to loosen secretions. In a 1-year randomised controlled trial (RCT) comparing oscillating PEP with PEP in children with CF, greater deterioration in pulmonary function and more hospitalisations were seen in the oscillating PEP group. However, a more recent 1-year study in adults showed no difference in lung function between groups randomly assigned to PEP or oscillating PEP. Auto-genic drainage (AD) uses controlled breathing to achieve the highest possible airflow in different generations of bronchi. Short-term studies have shown that AD is as effective as postural drainage and percussion, oscillating PEP and ACBT. In a long-term comparative study in adolescents with CF, AD was as effective as postural drainage, and participants showed strong preference for AD. Several systematic reviews note that no single ACT is superior, such that treatment choices should be individualized.

Postural drainage involves use of gravity to drain mucus from the lungs. A number of studies have demonstrated provocation of gastro-oesophageal reflux (GOR) during head-down tilted postural drainage in infants, children and adolescents with CF. Two additional studies did not reproduce these results in infants, with no differences in GOR between modified and traditional postural drainage; however, the head-down position utilized was not as steep, older infants were studied and they avoided the prone head-down tilted position. Other potential adverse effects of postural drainage with head-down tilt include increased dyspnoea and oxyhaemoglobin desaturation.

Modified postural drainage involves positioning without use of head-down tilt. In a 5-year follow-up of infants randomized to either standard or modified postural drainage, the modified group had fewer radiological changes and significantly better lung function at 6 years of age. In a short-term adult study comparing treatment in head-down versus horizontal positions, there was no difference in the amount of sputum expectorated, but patients reported fewer side effects in horizontal positions.

Physical exercise that increases minute ventilation leads to the mobilization of pulmonary secretions and enhances airway clearance. Some people with mild CF lung disease use exercise together with forced expiration and coughing as a stand-alone ACT. Others with more extensive lung disease and larger volumes of sputum use exercise as an adjunct to a formal ACT regimen. Physiological effects of exercise include reduced mechanical impedance of sputum, enhanced expiratory flow rates and induction of coughing. A meta-analysis including three trials found that the addition of exercise to ACT significantly increased forced expiratory volume in 1 s (FEV1) compared with ACT alone. Whether exercise can be used as an alternative to formal ACT is less clear, with conflicting results across trials.

1 ACT should be performed across the lifespan in CF (C).

2 The ACBT is an effective form of airway clearance and can be used by people with acute and chronic lung disease independently or in conjunction with other ACT (B).
3 PEP therapy, oscillating PEP and AD are effective forms of airway clearance, which can be performed independently (B).

4 Postural drainage in head-down positions should not be used routinely in infants with CF (B) or in patients of any age with known or suspected GOR (C). Modified postural drainage is recommended in infants and young children where active participation in airway clearance therapy is not possible (B).

5 Physical exercise may be used to reduce mechanical impedance of sputum (B), achieve short-term improvements in pulmonary function (A) and improve ease of expectoration (B).

**INHALATION THERAPY**

Inhalation therapy is an important treatment for CF respiratory disease. Effective inhalation therapy is integral to the success of ACT and vice versa; as a result, physiotherapists should be adequately skilled in delivery of inhalation therapy in order to maximize the effectiveness of both treatments.

The main determinants of deposition pattern for nebulised medications are the breathing pattern during inhalation, droplet size and age/condition of the lung. A slower breath results in a more desirable peripheral deposition pattern, improved homogeneity of deposition and increased overall drug deposition. A slower steady breath with occasional deep breaths have traditionally been recommended to promote improved deposition. However, the specific device being utilized may determine the optimal breathing pattern. Given the varying physico-chemical behaviours of the nebulised medications in CF, it is important to use a nebuliser/compressor combination, which is effective for the specific preparation.

Nebulised medication should be taken via a mouthpiece to maximize delivery of the drug to the airways and avoid nasal filtration. Exceptions are in young children who may be unable to use a mouthpiece effectively, or where sinuses are a target of therapy, or those with acute dyspnoea. Bronchodilators should be delivered by metered dose inhaler unless there is clinical need for nebulisation.

Nebulised medication should be taken via a mouthpiece to maximize delivery of the drug to the airways and avoid nasal filtration. Exceptions are in young children who may be unable to use a mouthpiece effectively, or where sinuses are a target of therapy, or those with acute dyspnoea. Bronchodilators should be delivered by metered dose inhaler unless there is clinical need for nebulisation.

6 Where possible, nebulised medication should be taken via a mouthpiece (C).

7 To optimize dose delivery and treatment time, inhalation technique should be adapted to the device being used, including consideration of body position and concurrent ACT (C).

8 Bronchodilators should be delivered by metered dose inhaler unless there is clinical need for nebulisation (C).

9 Metered dose inhalers with spacer should be used for the administration of inhaled corticosteroids (B).

10 Hypertonic saline may be administered before or during ACT (B).

**EXERCISE ASSESSMENT AND TRAINING**

Measures of exercise capacity predict survival in children and adults with CF and those with better physical fitness have better quality of life. Structured exercise programmes for people with CF improve fitness and thoracic mobility, maintain bone mineral density and may slow the rate of pulmonary decline. A study involving over 200 people with CF conducted over 9 years showed that patients with higher levels of physical activity in daily life (encompassing all activities, not just exercise programmes) had a slower rate of FEV1 decline than those who were less active.

Exercise testing enables evaluation of exercise capacity, functional capacity, response to treatment and disease progression. For physiotherapists, exercise tests also provide the basis for exercise prescription. Commonly used field exercise tests in CF are the 6-min walk test, the modified shuttle walk test and the 3-min step test. More details regarding the conduct and choice of exercise test are provided in...
Supplementary Appendix S1. The 6-min walk test is considered a particularly important measure during preparation for lung transplantation in CF, providing guidance regarding the timing of referral. Both aerobic training and anaerobic training are beneficial in CF. Aerobic training results in improved maximum exercise capacity, strength and quality of life. Anaerobic training has positive effects on lactate levels, peak power and fat-free mass. Both types of exercise may have positive effects on pulmonary function. Exercise programmes have beneficial effects both during admission for acute exacerbations and for the stable outpatient. It is unclear whether home-based, unsupervised training programmes are equally as effective as supervised programmes.

The ideal exercise prescription for people with CF has not been established. In the absence of specific guidelines, aerobic exercise prescription should follow the same principles as those used in healthy individuals and patients with other chronic respiratory diseases. Exercise training should occur on at least 3 days (preferably 5 or more days) per week, have a duration of 30 min per session and increase heart rate to 75% of maximum heart rate. A combination of aerobic and resistance training is required to achieve maximum benefits. Patients with CF may exhibit exercise-induced oxygen desaturation during training, even when pulmonary function is well preserved. Supplemental oxygen during exercise increases exercise duration, whether this improves clinical outcomes is not clear. Supplemental oxygen is frequently used during training in patients whose oxygen saturation falls below 90% during exercise.

11 Exercise is recommended for people with CF throughout the lifespan (B).
12 An exercise test should be considered to assess response to therapy in the inpatient and outpatient settings and as an assessment tool in the prescription of exercise training programmes (C).
13 A 6-min walk test should be performed as part of the initial assessment for lung transplantation (C).
14 Exercise prescription should be tailored to the individual and comply with recommended exercise guidelines (B).
15 Supplemental oxygen should be considered during training in patients with severe exercise-induced desaturation (C).

MUSCULOSKELETAL COMPLICATIONS OF CF

Musculoskeletal manifestations of CF arise as a result of multifactorial abnormalities in bone mineralization, altered respiratory mechanics and muscular imbalance secondary to pulmonary disease. Between 43% and 94% of individuals with CF experience spinal pain which occurs across the spectrum of disease severity. Musculoskeletal pain in CF is associated with decreased quality of life, increased respiratory symptoms, sleep disturbance, anxiety, depression and a reduced ability to perform ACT and exercise.

People with CF have multiple risk factors for inadequate bone mineralisation. Longitudinal studies have shown that bone gains during puberty are decreased in CF adolescents compared with healthy controls, resulting in decreased attainment of peak bone mass. A meta-analysis reported that in CF, the prevalence of osteoporosis and osteopenia was 23.5% and 38%, respectively. Individuals with more severe lung disease, decreased physical activity and low aerobic capacity had the lowest bone mineral density, higher prevalence of vertebral fractures and more severe kyphosis.

Weight-bearing exercise is the most effective non-pharmacological method to improve bone mineral density in the healthy population by stimulating bone accretion, preventing bone loss and improving bone structural qualities. As the foundation of bone health begins in childhood and there is some evidence of sustained benefit from early vigorous physical activity, children and adolescents should engage in high-impact weight-bearing exercise for 30 min three times a week. The prepubertal and early pubertal years are particularly important to help maximize peak bone mass as approximately one quarter of peak bone mass is gained in the 2 years around the pubertal growth spurt.

Changes in muscle strength, length and neuromuscular recruitment have been demonstrated in CF. Reduced lean muscle mass is associated with malabsorption and deconditioning. Peripheral muscle impairment is also noted in response to systemic inflammation and lack of moderate to vigorous physical activity. In CF, resistance training programmes of moderate to high intensity and variable duration (19 days to 12 months) have produced significant leg strength gains. Strength training for children is still a novel area with protocols not clearly defined; this is an area for future research.

Physiotherapists require the skills to manage a diverse range of musculoskeletal complications including CF-related arthropathy, sports injuries, spinal pain and pain associated with coughing. Early reports regarding the use of manual therapy and exercise in the management of pain and restriction are encouraging. Patients with CF-related arthropathy require rheumatological management, which may include physiotherapy interventions targeting pain reduction and muscle strengthening.
PHYSIOTHERAPY MANAGEMENT OF THE COMPLEX PATIENT

Cystic fibrosis is a complex multisystem disease, and patients often experience complications and comorbidities that have implications for physiotherapy management. These include haemoptysis, pneumothorax, cystic fibrosis-related diabetes (CFRD) and pregnancy.

There are no published data regarding physiotherapy management of patients with haemoptysis or pneumothorax; however, guidelines based on expert opinion are available. When haemoptysis is present, the physiotherapists aim to maintain adequate airway clearance and exercise regimens whilst promoting venous healing and minimizing the risk of re-bleeding. When a pneumothorax is present, physiotherapists aim to ensure that adequate airway clearance continues whilst minimizing the amount of positive pressure generated inside the patient’s lungs. Both of these situations may require alteration to usual ACT.

Cystic fibrosis-related diabetes is a frequent comorbidity in CF, occurring in 5–30% of patients. The American Diabetes Association Clinical Care Guidelines for CFRD state that people with CFRD should perform moderate aerobic exercise for at least 150 min per week, should monitor blood glucose levels before vigorous physical activity and may need to consume extra carbohydrate or alter their insulin dose (level of evidence – expert opinion). During periods of acute illness or courses of corticosteroids, blood sugar levels and insulin requirements may be altered and more careful monitoring required.

Many pregnancy-related physiological changes have implications for optimal physiotherapy care, although little research is available. Women with CF are encouraged to approach pregnancy with a regular ACT routine. Head-down tilted postural drainage should be avoided, along with any ACT that exacerbates nausea. Upright sitting is usually the most comfortable position for airway clearance. Modifications to exercise programmes may be required to accommodate musculoskeletal, respiratory and cardiac changes. Maintenance of adequate hydration during exercise should be emphasized. It is important to consider the need for domestic support during pregnancy and afterwards, to provide sufficient time for regular airway clearance, inhalation therapy and exercise.

PHYSIOTHERAPY MANAGEMENT OF CONTINENCE

The reported prevalence of urinary incontinence in girls and women with CF ranges from 22% to 74% in comparison with 13% in healthy women of similar age. There is limited literature in adult men with CF, with a reported prevalence of 8–15%, compared with 7.5% in healthy men. It is not known whether the cause of urinary incontinence in CF is chronic cough, loading of the pelvic floor during ACT, coughing and physical exercise, or underlying structural differences. People with CF and incontinence report increased anxiety and depression and a negative impact on quality of life.

Screening for incontinence should be part of routine physiotherapy care for both male and female patients. Treatment of urinary incontinence in women with CF by a continence physiotherapist with exercise, electrical stimulation, biofeedback and bladder training results in improvements in pelvic floor strength, reduction in leakage and improvement in quality of life. Positive outcomes have also been demonstrated with surgical correction of severe urinary incontinence in women with CF. In order to optimize pelvic floor function, patients should be taught to perform ACT in positions that maintain a neutral lumbar spine, with addition of perineal support in those with urinary incontinence.

19 Women with CF and symptoms of stress urinary incontinence should be taught rehabilitative strength and endurance exercises to provide better control of the pelvic floor.
20 Men and women with CF should be screened for symptoms of stress urinary incontinence.
21 Airway clearance should take place in postures that maintain a neutral lumbar spine, to optimize pelvic floor function.

PHYSIOTHERAPY MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT

Newly diagnosed infants and their families should meet with the CF multidisciplinary team soon after diagnosis. The role of physiotherapy in ACT, exercise and active play should be explained, demonstrated and practised. Treatment of infants should follow the usual guidelines for physiotherapy in CF, consisting of five modified postural drainage positions performed one to two times daily as appropriate. Each position, percussion or thoracic compressions should be performed for 3–5 min. Other techniques such as infant PEP or assisted AD can also be introduced. Normal developmental play and prone lying should be encouraged as the first steps towards an active physical lifestyle and routine.

Adults and children with a new diagnosis of CF usually have milder disease than those diagnosed in infancy. Some newly diagnosed adults are very well; therefore, physical exercise, huffing and coughing may be appropriate as stand-alone ACT. Those patients with established lung disease should be taught appropriate ACT and exercise regimens and educated about the role of nebulised drugs in their treatment.

22 Treatment for newly diagnosed infants may include percussion for 3–5 min in each of five modified postural drainage positions (B) and daily age-appropriate physical play (C).
23 Physiotherapy treatment for the newly diagnosed child and adult should include regular physical exercise (B); other forms of airway clearance therapy should be added as required (C).
NON-INVASIVE VENTILATION FOR CF

A number of descriptive studies report the successful use of non-invasive ventilation (NIV) to stabilize patients with CF and acute respiratory failure, with reduced hypercapnia, respiratory rate and dyspnoea. Although NIV does not reverse the respiratory deterioration inherent in end-stage disease, it may allow the patient to be stabilized for long enough for donor lungs to become available for transplantation. The use of NIV for CF patients who are not awaiting lung transplantation has also been reported where it may be useful for palliation of dyspnoea in end-stage disease.

Hypoxia and hypercapnia occur commonly during sleep in moderate to severe CF and may result in daytime respiratory failure. Positive short-term effects of NIV during sleep in CF have been reported. Longer-term outcomes of NIV for chronic respiratory failure may include improvements in daytime PaCO2, reduction in the number of days spent in hospital and improvement in symptoms. In a randomized controlled trial, domiciliary NIV over a 6-week period resulted in significant improvements in quality of life, respiratory symptom scores, dyspnoea, nocturnal ventilation and increased exercise performance.

Airway clearance techniques are onerous for patients who are unwell, because of increased ventilatory demand, alterations in gas exchange and dyspnoea. Two randomized crossover trials report that a single session of NIV can unload the respiratory muscles during ACT in both adults and children with CF, resulting in decreased dyspnoea and less desaturation. Similar effects have been observed with the application of NIV during exercise, including improved ventilation, reduced desaturation and increased functional walking performance. This may be useful in patients bridging to transplantation, in whom maintenance of exercise capacity is an important goal.

Non-invasive ventilation delivers air at high flow rates and low relative humidity, which may overwhelm the capacity of the upper airway mucosa to warm and humidify inspired air. Humidity levels during NIV are low enough to cause airway drying. This is of greatest concern in patients with excessive secretions, who are at high risk of sputum retention. Hence, consideration should be given to heated humidification when NIV is used in CF.

24 NIV should be considered in all patients with acute respiratory failure who are listed for transplantation.
25 In patients with symptomatic nocturnal ventilatory failure, a trial of nocturnal NIV may be undertaken.
26 NIV is a useful adjunct to airway clearance in patients with severe disease in whom dyspnoea and fatigue limit effective airway clearance.
27 NIV may be a useful adjunct to exercise in patients with severe disease where dyspnoea and fatigue contribute to deconditioning and limit effective training.

PHYSIOTHERAPY AND LUNG TRANSPLANTATION

There are many systemic features of CF that have the potential to impact on lung transplant suitability and outcomes, including skeletal muscle weakness and poor bone health. Most adult transplant centres offer dedicated preoperative exercise training classes for transplant candidates, in order to optimize physical fitness and strength. A recent large, retrospective study that included 70 people with CF showed that 6-min walk distance was well maintained from listing to transplantation in those who undertook thrice-weekly supervised exercise training. Furthermore, those with a greater 6-min walk distance prior to transplantation had a shorter hospital stay post-transplantation.

Exercise rehabilitation is an established therapy for lung transplant recipients. Although studies in CF are uncontrolled, 3 months of post-transplant rehabilitation has been associated with improvements in functional exercise capacity, strength and quality of life in adults and children. A recent randomized controlled trial of 3 months of rehabilitation in lung transplantation recipients with other respiratory disorders, performed immediately following hospital discharge, showed significant improvements in daily physical activity, quadriceps force and exercise performance at 1 year following transplantation. The content of post-transplantation rehabilitation programmes generally includes aerobic and resistance exercise, performed at least three times per week. Although most rehabilitation takes place in a group setting, patients with resistant organisms may require isolation from other immune-suppressed patients.

28 Heated humidification should be incorporated into the circuit for all applications of NIV in CF.

END OF LIFE CARE

There is no published literature specifically addressing physiotherapy treatment in the terminal stages of CF. However, many people with CF die of respiratory failure and physiotherapists are often involved with provision of end of life care. The aims of physiotherapy treatment will be influenced by whether the patient is actively waiting for transplantation. Care should focus on comfort and dignity and be tailored to each patient’s goals and values. Minimizing the work of breathing during ACT is an important consideration in those approaching the end of life. Some patients may require therapist-assisted ACT such as percussion or thoracic compressions. Airway clearance may be continued even in the palliative stage if the patient finds it beneficial to relieve symptoms.
measures such as soft tissue massage and positioning can also be considered.

INFECTION CONTROL

Respiratory pathogens have a significant impact on morbidity and mortality in CF,1,2 and good infection control practices are critical to preventing their transmission. Segregation and cohorting of inpatients and outpatients according to respiratory organisms are now routinely practised.176,177 Physiotherapists are encouraged to be familiar with their local infection control policies. Because of considerable variation in local policies, formal recommendations are not provided here.

Both Pseudomonas aeruginosa and Burkholderia cepacia may be spread in droplet form by coughing and can survive on dry surfaces for a number of days.178–180 There is also potential for airborne transmission.181 B. cepacia has been isolated from the hospital rooms and hands of patients following airway clearance182–184 and the outside surfaces of sputum cups.185 These findings reinforce the need to segregate patients whilst performing ACT and inhalation therapy, as well as the importance of hand washing. Stethoscopes should be cleaned with alcohol wipes between patients.185

Bacterial contamination of home nebulisers has been documented, and sharing equipment has been associated with transmission of B. cepacia.186–188 Under no circumstances should any respiratory equipment be shared between patients with CF. There is no consensus regarding the use of gloves, gowns and masks during physiotherapy treatment in CF. Physiotherapists should consult their local infection control policy with regard to when these measures are required.

Coughing is common during exercise, and droplet spread of organisms is possible. These droplets may be transmitted within 1 m of an infected patient.178 It has been reported that contamination can still occur between 1 and 2 m, albeit with lower probability (1.7%).189 As a result, patients with different organisms, or in different cohorts, do not exercise together. When people considered suitable for cohorting are sharing the gym, universal precautions should be practised. Patients should be educated to maintain a 2-m distance from other patients at all times, hands should be washed on entering and leaving the gym and patients should be taught to wipe down all exercise equipment with an alcohol-based solution before and after use.

PHYSIOTHERAPY SERVICES FOR CF

There is no published research regarding the optimum structure of physiotherapy services for people with CF. For inpatients, expert clinical opinion suggests that physiotherapy assessment and treatment starts on the day of hospital admission.190 The physiotherapy treatment plan should address inhalation therapy, ACT and exercise. Patients admitted with an acute exacerbation with increased and/or retained secretions will need to carry out more frequent ACT sessions than their baseline daily regimen. The number of treatments will range from two to three or more treatments in 24 h. A graduated physical exercise programme incorporating cardiorespiratory exercise should be commenced as soon as possible.

Patients attending the outpatient department of a Cystic Fibrosis Service should have access to a physiotherapist with expertise in CF management at each clinic visit. It is suggested that each patient be assessed three to six monthly so that their physiotherapy programme can be reviewed and optimized. Complex patients may require more frequent and detailed review. A formal annual review by the CF team, including physiotherapy review, has been advocated for people with CF.190,191

REFERENCES

1 Physiotherapy for cystic fibrosis in australia: a consensus statement. [Accessed 20 March 2015.] Available from URL: http://www.thoracic.org.au/documents/papers/physiotherapyforcf.pdf.
Physiotherapy guidelines for cystic fibrosis

2 Holland AE, Button BM. Physiotherapy for cystic fibrosis in Australia: knowledge and acceptance of the Consensus Statement recommendations. *Respirology* 2013; 18: 652–6.

3 National Health and Medical Research Council. 2009. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. [Accessed: 20th March 2015.] Available from URL: https://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_evidence_120423.pdf.

4 Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. *Chest* 2004; 125: 13–39.

5 van der Schans C, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. *Cochrane Database Syst. Rev.* 2003; 3: 3.

6 Desmond KJ, Schwenk WF, Thomas E, Beaudry PH, Coates AL. Physiotherapy in cystic fibrosis adult care: consensus conference report. *Chest* 2004; 125: 13–39.

7 Prasad A. Physiotherapy in cystic fibrosis. *J. R. Soc. Med.* 2000; 93: 27–36.

8 Pryor J. Active cycle of breathing techniques. In: McInwaine M, Van Ginderdeuren F (eds) *Physiotherapy in the Treatment of Cystic Fibrosis*, 3rd edn. International Physiotherapy Group/ Cystic Fibrosis, Karup, Denmark, 2009; 5–7.

9 Pryor J, Webber B, Hodson M, Bater J. Evaluation of the forced expiration technique as an adjunct to postural drainage in the treatment of cystic fibrosis. *Br. Med. J.* 1979; 2: 417–8.

10 McKoy NA, Saldanha IJ, Odelola OA, Robinson KA. Active cycle of breathing technique for cystic fibrosis. *Cochrane Database Syst. Rev.* 2012; 12 CD007862.

11 Lannefors L, Eriksson L. Positive expiratory pressure (PEP). In: McInwaine M, Van Ginderdeuren F (eds) *Physiotherapy in the Treatment of Cystic Fibrosis*, 3rd edn. International Physiotherapy Group/ Cystic Fibrosis, Karup, Denmark, 2009; 12–4.

12 Elkins MR, Jones A, van der Schans C. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. *Cochrane Database Syst. Rev.* 2006 CD003147.

13 Althaus P. Oscillating PEP - flutter therapy. In: McInwaine M, Van Ginderdeuren F (eds) *Physiotherapy in the treatment of cystic fibrosis*, 3rd edn. International Physiotherapy Group/ Cystic Fibrosis, Karup, Denmark, 2009; 18–22.

14 McInwaine PM, Wong LT, Peacock D, Davidson AG. Long-term comparative trial of positive expiratory pressure versus oscillating positive expiratory pressure (flutter) physiotherapy in the treatment of cystic fibrosis. *J. Pediatr.* 2001; 138: 845–50.

15 Newbold M, Tullis E, Corey M, Ross B, Brooks D. The flutter device versus the PEP mask in the treatment of adults with cystic fibrosis. *Physiother. Can.* 2005; 57: 199–207.

16 Ghevvalier J. Autogenic drainage (AD). In: McInwaine M, Van Ginderdeuren F (eds) *Physiotherapy in the Treatment of Cystic Fibrosis (CF)*. International Physiotherapy Group/ Cystic Fibrosis, 2009; 8–9.

17 Giles DR, Wagener JS, Accurso FJ, Butler-Simon N. Short-term effects of postural drainage with clapping vs autogenic drainage on oxygen saturation and sputum recovery in patients with cystic fibrosis. *Chest* 1995; 108: 952–4.

18 App EM, Kieselmann F, Reinhardt D, Lindemann H, Dasgupta B, King M, Brand P. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage. *Chest* 1998; 114: 171–7.

19 Miller S, Hall DO, Clayton CB, Nelson R. Chest physiotherapy in cystic fibrosis: a comparative study of autogenic drainage and the active cycle of breathing techniques with postural drainage. *Thorax* 1995; 50: 165–9.

20 McInwaine M, Wong LT, Chivers M, Davidson GF. Long-term comparative trial of two different physiotherapy techniques; postural drainage with percussion and autogenic drainage, in the treatment of cystic fibrosis. *Pediatr. Pulmonol.* 2010; 45: 1064–9.

21 Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. *Cochrane Database Syst. Rev.* 2009 CD006842.

22 Button BM, Heine RG, Catto-Smith AG, Phelan PD, Olinisky A. Postural drainage and gastro-oesophageal reflux in infants with cystic fibrosis. *Arch. Dis. Child.* 1997; 76: 148–50.

23 Vandenplas Y, Dierickx A, Blecker U, Lanciers S, Deneyer M. Esophageal pH monitoring data during chest physiotherapy. *J. Pediatr. Gastroenterol. Nutr.* 1991; 13: 23–6.

24 Button BM, Heine RG, Catto-Smith AG, Phelan PD. Postural drainage in cystic fibrosis: is there a link with gastro-oesophageal reflux? *J. Paediatr. Child Health* 1998; 34: 330–4.

25 Phillips GE, Pike SE, Rosenthal M, Bush A. Holding the baby: head downwards positioning for physiotherapy does not cause gastro-oesophageal reflux. *Eur. Respir. J.* 1998; 12: 954–7.

26 Doumit M, Krishnan U, Jaffe A, Belessis Y. Acid and non-acid reflux during physiotherapy in young children with cystic fibrosis. *Pediatr. Pulmonol.* 2012; 47: 119–24.

27 Cecins N, Jenkins S, Pengelly J, Ryan G. The active cycle of breathing techniques - to tip or not to tip? *Respir. Med.* 1999; 93: 660–5.

28 McDonnell T, McNicholas WT, FitzGerald MX. Hypoxaemia during chest physiotherapy in patients with cystic fibrosis. *Ir. J. Med. Sci.* 1986; 155: 345–8.

29 Button BM, Heine RG, Catto-Smith AG, Olinisky A, Phelan PD, Ditchfield MR, Story I. Chest physiotherapy in infants with cystic fibrosis: to tip or not? A five-year study. *Pediatr. Pulmonol.* 2003; 35: 208–13.

30 Hebestreit A, Kersting U, Basler B, Jeschke R, Hebestreit H. Exercise inhibits epithelial sodium channels in patients with cystic fibrosis. *Ann. J. Respir. Crit. Care Med.* 2001; 164: 443–6.

31 Lannefors I, Wollmer P. Mucus clearance with three chest physiotherapy regimes in cystic fibrosis: a comparison between postural drainage, PEP and physical exercise. *Eur. Respir. J.* 1992; 5: 748–53.

32 Salt W, Bilston D, Dodd M, Webb AK. Effect of exercise and physiotherapy in aiding sputum expectoration in adults with cystic fibrosis. *Thorax* 1989; 44: 1006–8.

33 Zach M, Oberwaldner B, Hauser F. Cystic fibrosis: physical exercise versus chest physiotherapy. *Arch. Dis. Child.* 1982; 57: 587–9.

34 Dwyer TJ, Alison JA, McKeeough ZJ, Davikas E, Bye PT. Effects of exercise on respiratory flow and sputum properties in patients with cystic fibrosis. *Chest* 2011; 139: 870–7.

35 Bilston D, Dodd ME, Abbot JV, Webb AK. The benefits of exercise combined with physiotherapy in the treatment of adults with cystic fibrosis. *Respir. Med.* 1992; 86: 507–11.

36 Loughlin GM, Cota KA, Taussig LM. The relationship between flow transients and bronchial lability in cystic fibrosis. *Chest* 1981; 79: 206–10.

37 Macfarlane PI, Heaf D. Changes in airflow obstruction and oxygen saturation in response to exercise and bronchodilators in cystic fibrosis. *Pediatr. Pulmonol.* 1990; 8: 4–11.

38 Cerny FJ. Relative effects of bronchial drainage and exercise for in-hospital care of patients with cystic fibrosis. *Phys. Ther.* 1989; 69: 633–9.

39 Thomas J, Cook DJ, Brooks D. Chest physical therapy management of patients with cystic fibrosis: a meta-analysis. *Am. J. Respir. Crit. Care Med.* 1995; 151: 846–50.

40 Reix P, Aubert F, Werck-Gallois MC, Toutain A, Mazzocchi C, Moreux N, Bellon G, Rahiloum M, Kassai B. Exercise with incorporated expiratory manoeuvres was as effective as breathing techniques for airway clearance in children with cystic fibrosis: a randomised crossover trial. *J. Physiother.* 2012; 58: 241–7.

41 Boe J, Dennis JH, O’Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Driot P, Heslop K, Lannefors L. European Respiratory Society Guidelines on the use of nebulizers. *Eur. Respir. J.* 2001; 18: 228–42.

42 Laube BI, Bashani R, Falby RN, Zeilin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. *Chest* 2000; 118: 1069–76.

43 Nebulizer therapy. Guidelines. British Thoracic Society Neulizer Project Group. *Thorax* 1997; 52 (Supp. 2): 54–24.

44 Heijerman H, Westerman E, Conway S, Touw D, Doring G. Inhaled medications and inhalation devices for lung disease in...
patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 2009; 8: 295–315.

45 Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalepi P, Voshaar T. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37: 1308–31.

46 Laube BL, Geller DE, Lin TC, Dalby RN, Diener-West M, Zeitlin PL. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respir. Care 2005; 50: 1438–44.

47 Frischknecht-Christensen E, Norregaard O, Dahl R. Treatment of bronchial asthma with terbutaline inhaled by conesperm combined with positive expiratory pressure mask. Chest 1991; 100: 317–21.

48 Sites SW, Perry GV, Peddicord T, Cox G, McMillan C, Becker B. Effect of high-frequency chest wall oscillation on the central and peripheral distribution of aerosolised diethylene triamine penta-acetic acid as compared to standard chest physiotherapy in cystic fibrosis. Chest 2006; 129: 712–7.

49 Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst. Rev. 2011 CD007923.

50 Anderson P, Morton J. Evaluation of two different timings of recombinant human DNase nebulisation in children with cystic fibrosis. Pediatr. Pulmonol. 2007; 42: 624–30.

51 Wilson CJ, Robbins LJ, Murphy JM, Chang AB. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial. Pediatr. Pulmonol. 2007; 42: 1110–6.

52 van der Giessen LJ, de Jonge JC, Gosselink R, Hop WC, Tiddens HA. BbDNase before airway clearance therapy improves airway patency in children with CF. Pediatr. Pulmonol. 1991; 100: 317–21.

53 van der Giessen LJ, de Jonge JC, Gosselink R, Hop WC, Tiddens HA. BbDNase before airway clearance therapy improves airway patency in children with CF. Pediatr. Pulmonol. 2007; 42: 624–30.

54 Stites SW, Perry GV, Peddicord T, Cox G, McMillan C, Becker B. Effect of high-frequency chest wall oscillation on the central and peripheral distribution of aerosolised diethylene triamine penta-acetic acid as compared to standard chest physiotherapy in cystic fibrosis. Chest 2006; 129: 712–7.

55 Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. Ann. Intern. Med. 1992; 117: 887–93.

56 Pianosi P, Leblanc J, Almudevar A. Peak oxygen uptake and penta-acetic acid as compared to standard chest physiotherapy

57 Orenstein DM, Franklin BA, Doershuk CF, Hellerstein HK, Gernman KJ, Horowitz JG, Stern RC. Exercise conditioning and pulmonary rehabilitation and aerobic exercise training on physical fitness in young adults with cystic fibrosis: a European consensus. Joint Bone Spine 2003; 70: 327–31.

58 Schneiderman-Walker J, Pollock SL, Corey M, Wilkes DD, Canny GI, Pedder I, Reisman JJ. A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. Pediatr. Pulmonol. 2000; 30: 304–10.

59 Kuys S, Hall K, Peasey M, Wood M, Cobb R, Bell S. Gaming console exercise and cycle or treadmill exercise provide similar cardiovascular demand in adults with cystic fibrosis: a randomised crossover trial. J. Physiother. 2011; 57: 35–40.

60 Schmidt AM, Jacobsen U, Bregnballe V, Olesen HV, Ingemann-Hansen T, Thastum M, Oluf Schiotz P. Exercise and quality of life in patients with cystic fibrosis: a 12-week intervention study. J. Physiother. 2011; 57: 589–93.

61 van Asperen WP. Randomized controlled study of in-hospital exercise training programs in children with cystic fibrosis. Pediatr. Pulmonol. 2002; 33: 194–200.

62 Klijn PH, Oudschoon A, van der Ent CK van der Net J, Kimpen JL, Holders PJ. Effects of anaerobic training in children with cystic fibrosis: a randomized controlled study. Chest 2004; 125: 1299–305.

63 Schneiderman-Walker J, Pollock SL, Corey M, Wilkes DD, Canny GI, Pedder I, Reisman JJ. A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. Pediatr. Pulmonol. 2000; 30: 304–10.

64 Kuys S, Hall K, Peasey M, Wood M, Cobb R, Bell S. Gaming console exercise and cycle or treadmill exercise provide similar cardiovascular demand in adults with cystic fibrosis: a randomised crossover trial. J. Physiother. 2011; 57: 35–40.

65 Moorcroft AJ, Dodd ME, Morris J, Webb AK. Individualised unsupervised exercise training in adults with cystic fibrosis: a 1 year randomised controlled trial. Thorax 2004; 59: 1074–80.

66 American College of Sports Medicine. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness and flexibility in healthy adults. Med. Sci. Sports Exerc. 1998; 30: 975–91.

67 Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2013; 188: e13–64.

68 Bradley J, Howard J, Wallace E, Elborn S. Validity of a modified shuttle test in adult cystic fibrosis. Thorax 1999; 54: 437–9.

69 Mallory GB, Fullmer JJ, Vaughan DJ. Oxygen therapy for cystic fibrosis. Cochrane Database Syst. Rev. 2005 CD003884.

70 Pulmonary Rehabilitation. British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation. Thorax 2001; 56: 827–34.

71 Ravilly S, Robinson W, Suresh S, Wohl ME, Berde CB. Chronic pain in cystic fibrosis. Pediatr. Pulmonol. 1996; 18: 741–7.

72 Festini F, Ballarini S, Codamo T, Doro R, Loganes C. Prevalence of pain in adults with cystic fibrosis. J. Cyst. Fibros. 2004; 3: 51–7.

73 Botton E, Saraux A, Laselhe J, Sousse S, Le Goff P. Musculoskeletal manifestations in cystic fibrosis. Joint Bone Spine 2003; 70: 327–35.

74 Paraza RB, Maffulli N. Musculoskeletal involvement in cystic fibrosis. Bull Hosp Jt Dis. (New York, NY) 1999; 58: 37–44.

75 Tattersall R, Walshaw MJ. Back pain in adult patients with CF: effect of chronic steroid use and physiotherapy. J. Cyst. Fibros. 2001; 1.

76 Flume PA, Ciolo M, Gray S, Lester MK. Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. J. Cyst. Fibros. 2009; 8: 321–5.
Physiotherapy guidelines for cystic fibrosis

© 2016 The Authors
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology

Respirology (2016) 21, 656–667

87. Hayes M, Yaster M, Haythornthwaite JA, Riekert KA, McMillan KN, White E, Mogayzel PJ Jr, Lechtzin N. Pain is a common problem affecting clinical outcomes in adults with cystic fibrosis. *Chest* 2011; 140: 1598–603.

88. Kelemen L, Lee AL, Button BM, Presnell S, Wilson JW, Holland AE. Pain impacts on quality of life and interferes with treatment in adults with cystic fibrosis. *Physiother. Res. Int.* 2012; 17: 32–41.

89. Ravilly S, Robinson W, Suresh S, Wohl ME, Berde CB. Chronic pain in cystic fibrosis. *Pediatrics* 1996; 98: 741–7.

90. Sawicki GS, Sellers DE, Robinson WM. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. *J. Pain Symptom Manage.* 2008; 36: 372–80.

91. Sermet-Gaudelus I, De Villarary P, de Dreuzy P, Clairicia M, Vrieleyck S, Canoui P, Kirzenbaum M, Singh-Mali I, Agrario L, Salort M. Pain in children and adults with cystic fibrosis: a comparative study. *J. Pain Symptom Manage.* 2009; 38: 281–90.

92. Steneke SJ, Hughes A, Gregoire MC, Frager G, Robinson WM, McGrath PJ. Frequency and self-management of pain, dyspnea, and cough in cystic fibrosis. *J. Pain Symptom Manage.* 2009; 38: 837–48.

93. Koh JL, Harrison D, Palermo TM, Turner H, McGraw T. Assessment of acute and chronic pain symptoms in children with cystic fibrosis. *Pediatr. Pulmonol.* 2005; 40: 330–5.

94. Eksterowicz N. Pain management in cystic fibrosis. *Pediatr. Pulmonol.* 2000; 30 Suppl. 20: 114–5.

95. Chastain DC, Cook AJ. Chronic pain in CF: associated beliefs and behaviours. *Pediatr. Pulmonol.* 2000; 30 Suppl. 20: 116–7.

96. Grey V, Atkinson S, Drury D, Casey L, Button BM, Presnell S, Wilson JW, Holland AE. Psychologic effects of nutritional status and hyperinflation on respiratory muscle strength in children and young adults. *Am. Rev. Respir. Dis.* 1990; 141: 1506–9.

97. Land JC, Heigenhauser GJ, Jones NL. Respiratory and peripheral muscle function in cystic fibrosis. *Am. Rev. Respir. Dis.* 1993; 147: 865–9.

98. Lamhonwah AM, Bear CE, Huan LJ, Kim Chiaw P, Ackerley CA, Tein I. Cystic fibrosis transmembrane conductance regulator in human muscle: dysfunction causes abnormal metabolic recovery in exercise. *Ann. Neurosci.* 2010; 16: 802–8.

99. Burtin C, Van Remoortel H, Vrijens B, Langer D, Colpaert K, Gosselin R, Decramer M, Dupont L, Troosters T. Impact of exacerbations of cystic fibrosis on muscle strength. *Respir. Res.* 2013; 14: 46.

100. Grevenstein DM, Hovell MF, Mulvihill M, Keating KK, Hofstetter CR, Kelsey S, Morris K, Nixon PA. Strength vs aerobic training in children with cystic fibrosis: a randomized controlled trial. *Chest* 2004; 126: 1204–14.

101. Selvdavadi HC, Blimkie CJ, Meyers N, Mellis CM, Cooper PJ, Van Asperen PP. Randomized controlled study of in-hospital exercise training programs in children with cystic fibrosis. *Pediatr. Pulmonol.* 2002; 33: 194–200.

102. van Doorn N. Exercise programs for children with cystic fibrosis: a systematic review of randomized controlled trials. *Disabil. Rehabil.* 2010; 32: 41–9.

103. Lee A, Holdsworth M, Holland A, Button B. The immediate effect of neuromusculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis. J. *Cyst. Fibros.* 2008; 7: 79–81.

104. Sandsund CA, Roughton M, Hodson ME, Pryor JA. Musculoskeletal pain and ease of breathing in adults with cystic fibrosis: a systematic literature review with meta-analysis. *Calcif. Tissue Int.* 2010; 86: 1–7.

105. Tejero García S, Giraldez Sanchez MA, Cegudo P, Quintana Gallego E, Dapena J, Garcia Jimenez R, Cano Luis P, Gomez de Terreros I. Bone health, daily physical activity, and exercise tolerance in patients with cystic fibrosis. *Chest* 2011; 140: 475–81.

106. Janz KF, Letuchy EM, Eichenberger Gilmore JM, Burns TL, Torner JC, Willing MC, Levy SM. Early physical activity provides sustained bone health benefits later in childhood. *Med. Sci. Sports Exerc.* 2010; 42: 1072–8.

107. Baxter-Jones AD, Kontulainen SA, Faulkner RA, Bailey DA. A longitudinal study of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood. *Bone* 2008; 43: 1101–7.

108. Barry DW, Koth W. Exercise and the preservation of bone health. *J. Cardiopulm. Rehabil. Prev.* 2008; 28: 153–62.

109. Body JJ, Bergmann P, Boonen S, Boutsen Y, Bruyere O, Devogelaer JP, Goemmaere S, Hollevolte N, Kaufman JM, Milisen K. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. *Osteoporos. Int.* 2011; 22: 2769–88.

110. Boreham CA, McKay HA. Physical activity in childhood and bone health. *Br. J. Sports Med.* 2011; 45: 877–9.

111. Lands L, Desmond KJ, Demizio D, Pavilans A, Coates AL. The effects of nutritional status and hyperinflation on respiratory muscle strength in children and young adults. *Am. Rev. Respir. Dis.* 1990; 141: 1506–9.

112. Body JJ, Bergmann P, Boonen S, Boutsen Y, Bruyere O, Devogelaer JP, Goemmaere S, Hollevolte N, Kaufman JM, Milisen K. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. *Osteoporos. Int.* 2011; 22: 2769–88.

113. Boreham CA, McKay HA. Physical activity in childhood and bone health. *Br. J. Sports Med.* 2011; 45: 877–9.
127 White D, Stiller K, Roney F. The prevalence and severity of symptoms of incontinence in adult cystic fibrosis patients. *Physiother. Theory Pract.* 2000; 16: 35–42.

128 Orr A, McVeany RJ, Webb AK, Dodd ME. Questionnaire survey of urinary incontinence in women with cystic fibrosis. *BMJ* 2001; 322: 1521.

129 Nixon GM, Glazner JA, Martin JM et al. Urinary incontinence in female adolescents with cystic fibrosis. *Pediatrics* 2002; 110: e22.

130 Moran F, Bradley JM, Boyle I, Elborn JS. Incontinence in adult females with cystic fibrosis: a Northern Ireland survey. *Int. J. Clin. Pract.* 2003; 57: 182–3.

131 Vella M, Cartwright R, Cardozo L, Parsons M, Madge S, Burns Y. Prevalence of incontinence and incontinence-specific quality of life impairment in women with cystic fibrosis. *Neuromuscul. Disorders* 2009; 19: 886–9.

132 Browne WJ, Wood CJ, Desai M, Weller PH. Urinary incontinence in 9–16 year olds with cystic fibrosis compared to other respiratory conditions and a normal group. *J. Cyst. Fibros.* 2009; 8: 50–7.

133 Chiarelli P, Brown W, McElduff P. Leaking urine: prevalence and associated factors in Australian women. *Neuromuscul. Disorders* 1999; 18: 567–77.

134 Burge AT, Holland AE, Sherburn M, Wilson JW, Cox N, Basekaba TM, McNeer R, Morton J, Button BM. Prevalence and impact of incontinence in adult men with cystic fibrosis. *Respirology* 2011; 16: 57.

135 Gumery L, Hodgson G, Humphries N, Sheldon J, Stableforth D, Mackenzie W, Honeybourne D, Hawkins G. The prevalence of urinary incontinence in the adult male population of a regional cystic fibrosis centre. *J. Cyst. Fibros.* 2002; 1: S173.

136 Nankivel G, Caldwell P, Pellett J. Urinary incontinence in adolescent females with cystic fibrosis. *Paediatr. Respir. Rev.* 2010; 11: 95–9.

137 Button BM, Sherburn M, Chase J, Stillman B, Wilson J. Effect of a three months physiotherapeutic intervention on incontinence in women with chronic cough related to cystic fibrosis and COPD. *Paediatr. Pulmonol.* 2005; 40 (Suppl. 28): A369.

138 Helm JM, Langman H, Dodd ME, Ahsuwalia A, Jones AM, Webb AK. A novel solution for severe urinary incontinence in women with cystic fibrosis. *J. Cyst. Fibros.* 2008; 7: 501–4.

139 Sapsford RR, Richardson CA, Stanton WR. Sitting posture affects pelvic floor muscle activity in parous women: an observational study. *Aust. J. Physiother.* 2006; 52: 219–22.

140 Sawyer SM, Glazner JA. What follows newborn screening? An evaluation of a residential education program for parents of infants with newly diagnosed cystic fibrosis. *Pediatrics* 2004; 114: 411–6.

141 Merelle ME, Huisman J, Alderden-van der Vecht A, Taat F, Bezemer D, Griffioen RW, Brinkhorst D, Dankert-Roelse JE. Early versus late diagnosis: psychological impact on parents of children with cystic fibrosis. *Pediatrics* 2003; 111: 346–50.

142 Kerem E, Conway S, Elborn S, Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. *J. Cyst. Fibros.* 2005; 4: 7–26.

143 Physiotherapy in the treatment of cystic fibrosis. 2009. [Accessed: January 15th 2015.]. Available from: URL: https://www.ecfs.eu/jpg.cf/booklet.

144 Laneefors L, Button BM, McIlwaine M. Physiotherapy in infants and young children with cystic fibrosis: current practice and future developments. *J. R. Soc. Med.* 2004; 97 (Suppl. 44): 8–25.

145 Dennerstein U, Lannefors L, Hoglund P, Hellberg K, Johansson H, Lagerkvist AL, Ortefelt M, Sahlberg M, Eriksson L. Lung function in the aging Swedish cystic fibrosis population. *Respir. Med.* 2009; 103: 1076–82.

146 Hodson ME, Madden BP, Steven MH, Tsang VT, Yacoub MH. Non-invasive mechanical ventilation for cystic fibrosis patients—a potential bridge to transplantation. *Eur. Respir. J.* 1991; 4: 524–7.

147 Piper AJ, Parker S, Tonzillo PJ, Sullivan CE, Bye P. Nocturnal nasal IPPV stabilizes patients with cystic fibrosis and hypercapnic respiratory failure. *Chest* 1992; 102: 846–50.

148 Padman R, Lawless S, Von Nessen S. Use of BiPAP by nasal mask in the treatment of respiratory insufficiency in pediatric patients: preliminary investigation. *Pediatr. Pulmonol.* 1994; 17: 119–23.

149 Caronia CG, Silver P, Nimkoff L, Gorvoy J, Quinn C, Sagy M. Use of bilevel positive airway pressure (BiPAP) in end-stage patients with cystic fibrosis awaiting lung transplantation. *Clin. Pediatr.* 1998; 37: 555–9.

150 Sprague K, Graff G, Tobias DJ. Noninvasive ventilation in respiratory failure due to cystic fibrosis. *South. Med. J.* 2000; 93: 954–61.

151 Madden BP, Kariyawasam H, Siddiqui AJ, Machin A, Pryor JA, Hodson ME. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. *Eur. Respir. J.* 2002; 19: 310–3.

152 Flight WG, Shaw J, Johnson S, Webb AK, Jones AM, Bentley AM, Bright-Thomas RJ. Long-term non-invasive ventilation in cystic fibrosis – experience over two decades. *J. Cyst. Fibros.* 2012; 11: 187–92.

153 Muller NL, Francis PW, Gurwitz D, Leishon V, Bryan AC. Mechanism of hemoglobin desaturation during rapid-eye-movement sleep in normal subjects and in patients with cystic fibrosis. *Am. Rev. Respir. Dis.* 1980; 121: 483–9.

154 Topper RS, Skatrud JB, Dempsey JA. Ventilation and oxygenation changes during sleep in cystic fibrosis. *Chest* 1983; 84: 388–93.

155 Olson EJ, Simon PM. Sleep-wake cycles and the management of respiratory failure. *Chest.* 1996; 2: 500–6.

156 Goral D. Nocturnal ventilatory support in patients with cystic fibrosis: comparison with supplemental oxygen. *Eur. Respir. J.* 1997; 10: 1999–2003.

157 Milross MA, Piper AJ, Norman M, Becker HF, Willson GN, Grunstein RR, Sullivan CE, Bye PT. Low-flow oxygen and bilevel ventilatory support. Effects on ventilation during sleep in cystic fibrosis. *Am. J. Respir. Crit. Care Med.* 2001; 163: 129–34.

158 Hill AT, Edendborough FP, Cayton RM, Stableforth DE. Long-term nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure (1991–1996). *Respir. Med.* 1998; 92: 523–6.

159 Granot JT, Shapiro C, Kesten S. Noninvasive nocturnal ventilatory support in advanced lung disease from cystic fibrosis. *Respir. Care* 2002; 47: 675–81.

160 Young AC, Wilson JW, Kotsimbos TC, Naughton MT. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. *Thorax* 2008; 63: 72–7.

161 Williams MT, Parsons DW, Frick RA, Ellis ER, Martin AJ, Giles SE, Grant ER. Acute respiratory infection in patients with cystic fibrosis with mild pulmonary impairment: comparison of two physiotherapy regimens. *Aust. J. Physiother.* 2001; 47: 236–37.

162 Hollands AE, Denehy L, Ntoumenopoulos G, Naughton MT, Wilson JW. Non-invasive ventilation assists chest physiotherapy in adults with acute exacerbations of cystic fibrosis. *Thorax* 2003; 58: 880–4.

163 Fauroux B, Boule M, Lofaso F, Zerah F, Clement A, Harf A, Isabey D. Chest physiotherapy in cystic fibrosis: improved tolerance with nasal pressure support ventilation. *Pediatrics* 1999; 103: 1–9.

164 Lima CA, de Andrade AF, Campos SL, Brandao DC, Fregonezi G, Mourato IP, Aliverti A, de Britto MC. Effects of noninvasive ventilation on treadmill 6-min walk distance and regional chest wall volumes in cystic fibrosis: randomized controlled trial. *Respir. Med.* 2014; 108: 1460–8.

165 Hollands AE, Denehy L, Buchan CA, Wilson JW. Efficacy of a heated passover humidifier during noninvasive ventilation: a bench study. *Respir. Care* 2007; 52: 38–44.

166 Wiest GH, Foerst MD, Fuchs FS, Schmelzer AH, Hahn EG, Ficker JH. In vivo efficacy of two heated humidifiers used during CPAP-therapy for obstructive sleep apnea under various environmental conditions. *Sleep* 2001; 24: 435–40.

167 Troosters T, Langer D, Vrijens B, Segers J, Wouters K, Janssens W, Gosselink R, Decramer M, Dupont L. Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. *Eur. Respir. J.* 2009; 33: 99–106.
Physiotherapy guidelines for cystic fibrosis

168 Li M, Mathur S, Chowdhury NA, Helm D, Singer LG. Pulmonary rehabilitation in lung transplant candidates. J. Heart Lung Transplant. 2013; 32: 629–32.

169 Wickerson L, Mathur S, Brooks D. Exercise training after lung transplantation: a systematic review. J. Heart Lung Transplant. 2010; 29: 497–503.

170 Munro PE, Holland AE, Bailey M, Button BM, Snell GI. Pulmonary rehabilitation following lung transplantation. Transplant. Proc. 2009; 41: 292–5.

171 Deliva RD, Hassall A, Manlhiot C, Solomon M, McCrindle BW, Munro PE, Holland AE, Bailey M, Button BM, Snell GI. Pulmonary medicine published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology © 2016 The Authors

172 Langer D, Burtin C, Schepers L, Ivanova A, Verleden G, Decramer M, Troosters T, Gosselink R. Exercise training after lung transplantation improves participation in daily activity: a randomized controlled trial. Am. J. Transplant. 2012; 12: 1584–92.

173 Davis PB. Clinical pathophysiology and manifestations of lung disease. In: Yankaskas JR (ed) Cystic Fibrosis in Adults, 1st edn. Lippincott-Raven, Philadelphia, 1999; 45–67.

174 Tonelli MR. End-of-life care in cystic fibrosis. Curr. Opin. Pulm. Med. 1998; 4: 332–6.

175 Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002; 57: 142–5.

176 Infection control guidelines for cystic fibrosis patients and carers. 2012. [Accessed: 15th January 2015 2015.] Available from URL: http://www.cysticfibrosis.org.au/cfa/infection-control.

177 Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, Downer VS, Fliege J, Hazle LA, Jain M et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect. Control Hosp. Epidemiol. 2014; 35 (Suppl. 1): S1–67.

178 Saiman L, Siegel J. Infection control in cystic fibrosis. Clin. Microbiol. Rev. 2004; 17: 57–71.

179 Zimkoff J, Holby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J. Hosp. Infect. 1983; 4: 31–40.

180 Festini F, Taccetti G, Mannini C, Campana S, Mergni G, Vignoli N, Allegretti N, Ravenni N, Cocchi P, Neri S et al. Patient risk of contact with respiratory pathogens from inanimate surfaces in a cystic fibrosis outpatient clinic. A prospective study over a four-year period. Pediatr. Pulmonol. 2007; 42: 779–94.

181 Wainwright CE, France MW, O’Rourke P, Amuj S, Kidd TJ, Nissen MD, Sloots TP, Coulter C, Ristovski Z, Hargreaves M et al. Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax 2009; 64: 926–31.

182 Moore JE, McIlhatton B, Buchanan J, Gilpin D, Shaw A, Hall V, Murphy PG, Elborn JS. Occurrence of Burkholderia cepacia in the hospital environment. Ir. J. Med. Sci. 2002; 171: 131–3.

183 Ensor E, Humphreys H, Peckham D, Webster C, Knox AJ. Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy? J. Hosp. Infect. 1996; 32: 9–15.

184 Pegues DA, Schidlow DV, Tablan OC, Carson LA, Clark NC, Jarvis WR. Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 1994; 148: 805–12.

185 Whittington AM, Whitlock G, Hewson D, Thomas C, Brett SJ. Bacterial contamination of stethoscopes on the intensive care unit. Anaesthesia 2009; 64: 620–4.

186 Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, Kaufmann ME, Pitt TL. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J. Clin. Microbiol. 1996; 34: 584–7.

187 Estivariz CF, Bhatti LI, Pati R, Jensen B, Arduino MJ, Jernigan D, Lipuma JJ, Srinivasan A. An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest 2006; 130: 1346–53.

188 Brzezinski LX, Riedi CA, Kuske P, Souza HH, Rosario N. Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients? J. Bras. Pneumol. 2011; 37: 341–7.

189 Festini F, Taccetti G, Gallici V, Neri S, Bisogni S, Cadà D, Braggion C. A 1-m distance is not safe for children with cystic fibrosis at risk for cross-infection with Pseudomonas aeruginosa. Am. J. Infect. Control 2010; 38: 244–5.

190 Bell SC, Robinson PJ, Fitzgerald DA. 2008. Cystic Fibrosis Standards of Care Australia. [Accessed: July 14 2013.] Available from URL: http://www.thoracic.org.au/imagesDB/wysiwyg/CF_standardsofcare_Australia_2008.pdf.

191 Standards of care for cystic fibrosis in New Zealand. 2010. [Accessed: July 14 2013.] Available from URL: http://www.thoracic.org.au/imagesDB/wysiwyg/CF_StanardsofCare_NZ2010.pdf.

Supplementary Information

Additional Supplementary Information can be accessed via the html version of this article at the publisher’s website:

Appendix S1 Physiotherapy for Cystic Fibrosis in Australia and New Zealand: A Clinical Practice Guideline - comprehensive version.

Any reference to the online supplement should cite this Respirology paper as the primary publication: Button BM, Wilson C, Dentice R, Cox N, Middleton A, Tannenbaum E, Bishop J, Cobb R, Burton K, Wood M, Moran P, Black R, Bowen S, Day R, Depiazzi J, Doiron K, Doumit M, Dwyer T, Elliot A, Fuller L, Hall K, Hutchins M, Kerr M, Lee A, Mans C, O’Connor L, Steward R, Potter A, Rasekaba T, Scoones R, Tarrant B, Ward N, West S, White D, Wilson L, Wood J, Holland AE. Physiotherapy for Cystic Fibrosis in Australia and New Zealand: A Clinical Practice Guideline. Respirology 2016; 21: 656-667.